Fenwick Represents Dexcom in $850 Million Convertible Senior Notes Offering

Fenwick & West represented Dexcom, Inc. (Nasdaq: DXCM), a leader in continuous glucose monitoring (CGM), in its private offering of $850 million of 0.75% Convertible Senior Notes due 2023 to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933.

The Fenwick transaction team included corporate lawyers Michael Brown, David Michaels, Robert Freedman, Julia Forbess, Amanda Baratz and Larry Suh; and tax lawyers Will Skinner and David de Ruig.